NEW YORK (GenomeWeb News) – Life Technologies today announced that it will sell cancer mutation assays supplied by TrimGen to the research market.

Under the collaboration, assays for detecting KRAS and BRAF mutations will be developed and manufactured by TrimGen, which will supply the assays to Life Technologies. The assays will be sold under the Applied Biosystems brand and run on AB's capillary electrophoresis sequencing systems, including its new 3500 Series Genetic Analyzer.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.